Quick answer: there is no generic tirzepatide approved in the US. Mounjaro and Zepbound, both made by Eli Lilly, are the only FDA-approved tirzepatide products.[2] The FDA cannot approve a generic before tirzepatide’s new chemical entity exclusivity ends on May 13, 2027, and Lilly’s listed patents run from May 2036 to December 2041.[1] Compounded tirzepatide is not a generic, and since early 2025 pharmacies generally cannot make copies of it.[3]
This guide explains the patent and exclusivity dates, why compounded versions are not generics, and what the FDA and courts have decided. For the drug itself, see our tirzepatide profile.
Is there a generic Mounjaro or Zepbound?
No. Mounjaro (approved May 2022) and Zepbound (approved November 2023) are the only FDA-approved tirzepatide products, according to an August 2026 federal appeals court opinion that reviewed the record.[2] The patents and exclusivity listed for tirzepatide in the FDA’s Orange Book still block generic approval.[1]
Products sold online as “tirzepatide” outside a licensed pharmacy, including those labeled “for research purposes” or “not for human consumption,” are not generics. The FDA says such products are being illegally sold for human use.[4]
Patents and exclusivity dates
Two kinds of protection keep generics off the market: regulatory exclusivity, granted by the FDA, and patents, listed in the FDA’s Orange Book. Here is what the Orange Book shows for Mounjaro (NDA 215866):[1]
| Protection | Type | Expires |
|---|---|---|
| New chemical entity (NCE) exclusivity | FDA exclusivity | May 13, 2027 |
| New patient population exclusivity | FDA exclusivity | December 19, 2028 |
| US patent 9,474,780 | Patent | May 13, 2036 |
| US patents 11,357,820; 12,453,755; 12,453,756; 12,629,404 | Patents | June 14, 2039 |
| US patents 12,343,382; 12,616,740 | Patents | July 22, 2039 |
| US patent 12,295,987 | Patent | December 30, 2041 |
What this means in practice:
- 2027 is the earliest possible date. The appeals court noted that the FDA is barred from approving another maker’s tirzepatide for five years after the first approval, and that Lilly’s exclusivity extends to 2027.[2]
- The patents matter more. A generic company would also need to wait for the relevant patents to expire, win a court challenge against them, or reach a settlement with Lilly. The earliest listed patent runs to May 2036.[1]
- Dates can change. Patent challenges, settlements and new listings can move the timeline in either direction. Exclusivity for a new patient group usually protects only that specific use.
How a generic tirzepatide would be approved
Tirzepatide is a peptide, but in the US it was approved through a standard new drug application (NDA 215866), the same route used for most small-molecule drugs.[1] A future generic would therefore go through the abbreviated generic pathway rather than the separate biosimilar pathway used for large biologic drugs.[2]
To be approved, a generic would need to show it has the same active ingredient as Mounjaro or Zepbound and works the same way in the body. The protections above apply to the active ingredient itself, which the appeals court described as the drug’s “active moiety,” so they cover both brands at once.[2] A generic of one brand would not arrive earlier than a generic of the other.
Two practical consequences follow:
- A generic pen is a separate hurdle. Mounjaro and Zepbound come in pens, vials and a multi-dose KwikPen.[5] Some of the later patents cover formulations and uses rather than the molecule itself, which can affect which versions a generic maker could sell and when.[1]
- Labels could differ. A generic may launch with only some of the brand’s approved uses if other uses are still protected.
Why compounded tirzepatide is not a generic
A generic drug must be approved by the FDA as equivalent to the brand. A compounded drug is mixed by a pharmacy and is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold.[4]
Compounded tirzepatide became widespread while the drug was in shortage. Federal law relaxes some compounding limits when a drug is on the FDA’s shortage list.[2] Mounjaro was added to that list in December 2022 and Zepbound in April 2024.[2]
More detail on how compounded versions differ is in our compounded tirzepatide guide.
How the shortage ended: FDA decisions and court rulings
| Date | Event |
|---|---|
| October 2, 2024 | FDA determines the tirzepatide shortage is resolved[3] |
| October 2024 | Compounders sue; FDA agrees to reevaluate (announced October 22)[2][3] |
| December 19, 2024 | FDA confirms the shortage is resolved and sets grace periods[3] |
| February 18, 2025 | Original end of grace period for 503A state-licensed pharmacies[3] |
| March 5, 2025 | District court in Texas denies the compounders’ request for a preliminary injunction; 503A grace period ends[3] |
| March 19, 2025 | Grace period ends for 503B outsourcing facilities[3] |
| Later in 2025 | District court grants summary judgment to the FDA and Lilly[2] |
| August 27, 2026 | Fifth Circuit Court of Appeals affirms, upholding the FDA’s decision[2] |
The appeals court found the FDA did not need formal notice-and-comment rulemaking, and that it reasonably relied on Lilly’s supply data over less reliable evidence such as screenshots and surveys.[2]
As of its April 1, 2026 reminder, the FDA says tirzepatide is not on its drug shortage list and not on the list of bulk substances outsourcing facilities may use.[3]
What the end of the shortage means for patients
For most people, the practical result is that tirzepatide now comes from Lilly’s approved products, filled with a prescription through a pharmacy or LillyDirect. As of the FDA’s April 2026 reminder, tirzepatide is not on the drug shortage list.[3] If you were using a compounded product, talk with your prescriber about moving to an approved one rather than stopping abruptly.
Safety concerns with unapproved tirzepatide
The FDA has received more than 730 adverse event reports linked to compounded tirzepatide as of May 31, 2026, and says the true number is likely higher because many pharmacies are not required to report.[4] It has also warned about fake products and fraudulent labels naming pharmacies that do not exist.[4]
Lower-cost options while there is no generic
- LillyDirect self-pay: Zepbound single-dose vials and the KwikPen start at $299 a month for 2.5 mg, with higher doses priced higher.[6]
- Insurance and Medicare: coverage depends on whether you are using tirzepatide for diabetes, weight or sleep apnea. See Zepbound vs Mounjaro.
- Other approved drugs: your prescriber may consider other options, such as semaglutide or the oral drug orforglipron.
Whatever the source, the dose schedule should follow the label, which starts at 2.5 mg weekly and rises in 2.5 mg steps.[5] See the tirzepatide dosage chart.
